Results 171 to 180 of about 13,721,448 (320)
Bleeding, Thrombosis and Vascular BiologyIntroduction. Cancer-associated thrombosis (CAT) is a frequent and clinically relevant complication in patients with malignancy. While inherited thrombophilia is a well-established risk factor for venous thromboembolism in the general population, its ...
Elena Campello
doaj
Clinical Pharmacology &Therapeutics, EarlyView.Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
Bart van Lieshout +3 more
wiley +1 more source
Right Ventricular Thrombus in a 36-Year-Old Man with Factor V Leiden
Journal of Tehran University Heart Center, 2015 Factor V Leiden deficiency is the most common hereditary hypercoagulable disease in the United States and involves 5% of the Caucasian population. Up to 30% of patients who present with deep vein thrombosis (DVT) or pulmonary thromboembolism present with
Shokoufeh Hajsadeghi +3 more
doaj
Clinical Pharmacology &Therapeutics, EarlyView.A mechanistic CNS PBPK model framework was applied to eight antipsychotic D2 receptor ligands, comparing brain extracellular fluid (brainECF) and brain cell membrane (brainM) as biophase for predicting human receptor occupancy compared against PET neuroimaging data. BrainM concentrations showed improved agreement with PET‐derived receptor occupancy for
Divakar Budda +2 more
wiley +1 more source
Real-world data on Factor V Leiden in Sweden: A nationwide family study [PDF]
Emina Curic +3 more
openalex +1 more source
Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset
Clinical Pharmacology &Therapeutics, EarlyView.Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit +6 more
wiley +1 more source
Firm‐Level Corporate Social Responsibility and Employees' Affective Outcomes: A Multilevel Approach
Corporate Social Responsibility and Environmental Management, EarlyView.ABSTRACT This study advances research on corporate social responsibility (CSR) and employees' work attitudes by distinguishing between employee‐level CSR perceptions and firm‐level CSR practices. Prior research has mainly focused on how employees' perceptions of CSR relate to their affective outcomes; this study extends that perspective by jointly ...
Alexander C. Kraaij +2 more
wiley +1 more source
Corporate Social Responsibility and Environmental Management, EarlyView.ABSTRACT Blue economy advocates the sustainable use of marine resources while fostering economic growth and environmental preservation. Yet many business sectors still pursue extractive practices that undermine marine ecosystems and disregard consumers' sensitivity.
Maria Irene Prete +2 more
wiley +1 more source